Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
Biostrata Ltd on behalf of Thermo
FOCUS DIAGNOSTICS, INC.

Test Being Developed to Diagnose Mild Cognitive Impairment

By Labmedica International staff writers
Posted on 18 Feb 2013
Autoantibody biomarkers in the blood can potentially be used to diagnose early stages of Alzheimer's and Parkinson's diseases.

A grant of USD 799,800 from the Osteopathic Heritage Foundation at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (Stratford, NJ, USA) will help expand earlier research conducted by Robert Nagele, PhD, director of the Biomarker Discovery Center (at the University). Dr. Nagele's published research includes recent findings that identify specific autoantibody biomarkers in the blood for early diagnosis of Alzheimer's and Parkinson's diseases.

The funded project will pursue three specific goals: to identify a small number of autoantibody biomarkers that can accurately (90% or higher) diagnose MCI cases caused by early stage Alzheimer's disease; to verify the accuracy rate with a larger scale study; and to construct and test a diagnostic kit that is maximally accurate for the broadest possible MCI patient population. If successful, the study will then apply for final US Food and Drug Administration (FDA; Silver Spring, MD, USA) approval of the test.

"Using our novel biomarker discovery strategy, we have shown that it is possible to use a single drop of blood to diagnose Alzheimer's and Parkinson's with greater than 95% accuracy," said Dr Nagele. "This same approach should also allow us to identify a small number of biomarkers that can also accurately diagnose MCI caused by early-stage Alzheimer's disease."

Current approaches to MCI diagnosis rely on physical, neurological, and psychiatric examinations, laboratory tests, and a thorough review of the patient's medications and medical history. Recently, great attention has been given to using neuroimaging technologies to detect structural changes in the brain before symptoms appear. However, these approaches require expensive equipment and technology and can require hospital visits, the injection of radioactive compounds, and the availability of radiologists with advanced training in these techniques.

While current treatments for Alzheimer's cannot stop the progression of the disease, several medications are capable of significantly enhancing brain performance and alleviating symptoms. A number of promising drugs are also currently under development and in clinical trials for the treatment of early Alzheimer's disease. An easy-to-administer blood test for MCI would give pharmaceutical companies a way to identify patients for clinical trials who are at a very early stage of their disease and give researchers a nearly immediate way to monitor the effectiveness of medications under examination.

Related Links:

University of Medicine and Dentistry of New Jersey
US Food and Drug Administration



KARL HECHT GMBH & CO KG
CELLAVISION AB
77 ELEKTRONIKA

Channels

Genetic Tests

view channel
Image: Histopathology of tuberculoid leprosy in a skin section (Photo courtesy Dr. D.S. Ridley, Wellcome Images).

Genes Discovered Influence Risk of Developing Leprosy

Leprosy, a chronic dermatological and neurological disease, is caused by infection with Mycobacterium leprae, and its manifestation, progression and prognosis are strongly associated with the proficiency... Read more

Hematology

view channel
Image: Phlebotomy or venipuncture performed to obtain blood for laboratory tests (Photo courtesy of Sweet Water Health and Education).

Excessive Phlebotomy in Cardiac Surgical Care Leads to Anemia

Laboratory testing among patients undergoing cardiac surgery can lead to excessive bloodletting, which can increase the risk of developing hospital-acquired anemia and the need for blood transfusion.... Read more

Industry News

view channel

Latin America’s IVD Sector Exceeds USD 2 Billion, Brazil leads

The Latin American in vitro diagnostics (IVD) sector was estimated at USD 2.4 billion in 2014. Population growth, government insurance, newly insured patients, and updated healthcare facilities have driven growth in the region and will continue to propel demand, according to Kalorama Information (New York, NY, USA).... Read more
 

Events

06 Apr 2015 - 08 Apr 2015
07 Apr 2015 - 09 Apr 2015
13 Apr 2015 - 16 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.